SLXN does not currently have a usable, up-to-date analyst consensus. Maxim Group's Naz Rahman, the most active covering analyst, downgraded the stock to Hold and removed his price target, citing delisting and dilution risk. The lone remaining reference is a $6.00 Buy initiated by Litchfield Hills in December 2025 — a figure that predates the company's 1-for-10 reverse split in May 2026 and its 1-for-24 reverse split in November 2026 and has not been restated. Because fewer than two credible, current targets exist, the $6.00 figure is used here strictly as a publicly discussed price objective, not as an analyst consensus. It rests on identifiable public commentary that continues to circulate, and readers should treat it as a legacy reference point rather than a fresh forecast.
Silexion Therapeutics is a clinical-stage biotechnology company developing RNAi (RNA interference) therapies for KRAS-driven cancers. Its lead candidate, SIL204, is a second-generation siRNA (small interfering RNA) being evaluated in a Phase 2/3 trial for locally advanced pancreatic cancer. The shares closed near $3.23 on November 11, 2026, the first session of split-adjusted trading. Reaching $6.00 would require a rise of about 86% — a very large move by any standard, and one that, for a pre-revenue company, would hinge less on near-term financials than on clinical and financing news.
The clearest positive is execution on SIL204. The company has dosed its first patient in the global Phase 2/3 program and reported supportive preclinical findings on SIL204's uptake and gene-silencing mechanism. In oncology, particularly in an area of high unmet need such as pancreatic cancer, favorable trial updates or regulatory milestones can drive sharp re-ratings even for micro-cap developers. The reverse split itself was framed by management as a step to restore Nasdaq bid-price compliance, broaden the eligible investor base, and preserve access to equity financing needed to fund the trial.
The risks are substantial and structural. Silexion has completed four reverse splits since its 2024 listing, reflecting persistent share-price deterioration. The company generates no revenue, posts ongoing losses, and its auditor has expressed substantial doubt about its ability to continue as a going concern. It remains dependent on repeated dilutive equity raises, which pressure the share price. Nasdaq compliance and potential delisting remain live risks, and any negative or delayed clinical data on SIL204 could remove the primary catalyst. These factors make the $6.00 objective difficult to reach without sustained favorable developments.
After a 1-for-24 reverse split, meaningful durable technical levels are unreliable because historical price comparisons are distorted by repeated share consolidations. The most relevant threshold is behavioral rather than chart-based: the Nasdaq $1.00 minimum bid price, which the reverse split was designed to satisfy. Until the stock establishes a sustained post-split trading range, conventional support and resistance levels carry limited predictive value.
Analyst price targets generally reflect a roughly 12-month research horizon, but the $6.00 reference here carries no such explicit timeframe because it is a legacy figure. Investors should monitor trial enrollment and any interim safety or efficacy readouts from the SIL204 Phase 2/3 program, further financing announcements and their dilutive effect, cash runway updates relative to the going-concern disclosure, and any Nasdaq listing developments. Because reverse splits and capital raises have repeatedly reset the share count, tracking share-count changes matters as much as tracking the price.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For a volatile micro-cap such as SLXN, where fundamentals and structure change quickly, systematic signal tools can help investors stay oriented as conditions evolve.
The question of whether Silexion Therapeutics can reach $6.00 comes down to a single, unforgiving tension. On one side, a real Phase 2/3 clinical program and a hot oncology target offer genuine upside catalysts. On the other, a going-concern warning, recurring dilution, four reverse splits in roughly two years, and a withdrawn analyst target describe a company under severe structural pressure. The $6.00 objective is a legacy, publicly discussed figure rather than a current analyst consensus, and the roughly 86% move required is very large. Whether the shares approach it will likely be determined less by valuation than by clinical data, financing terms, and the company's ability to hold its Nasdaq listing — none of which can be forecast with confidence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.
| Ticker / NAME | Correlation To SLXN | 1D Price Change % | ||
|---|---|---|---|---|
| SLXN | 100% | -11.22% | ||
| IMA - SLXN | 62% Loosely correlated | -4.03% | ||
| CELC - SLXN | 50% Loosely correlated | -4.72% | ||
| CDT - SLXN | 44% Loosely correlated | -33.19% | ||
| INKT - SLXN | 36% Loosely correlated | -1.38% | ||
| HYFT - SLXN | 34% Loosely correlated | -4.63% | ||
More | ||||